ebook Munafa Stock Market Course + Intraday & FNO calls  

       

524816 announcements Natco Pharm announcements and dividends declared BSE

Natco Pharm Complete list of announcements declared & dividend announcements by Natco Pharm 524816

Natco Pharm 524816 listed on BSE and deals in

Announcements and dividends declared by Natco Pharm 524816

Natco Pharma's Kothur unit classified as 'voluntary action indicated' by US regulator
Natco Pharma Ltd announced that its Kothur unit in Hyderabad received an Establishment Inspection Report (EIR) from the US FDA, classifying the facility as 'Voluntary Action Indicated' (VAI). The US FDA had previously conducted an inspection of the company
Announcement as on 18 September 2025

Natco Pharma sues Novo Nordisk in generic drug push
The lawyers representing Natco Pharma informed the court that over the past few months it had approached Novo Nordisk to communicate on its non-infringing patents but received no response, said people familiar with the matter. "A clear communication from t
Announcement as on 21 August 2025

Natco Pharma launches generic drug with 180-day exclusivity in US
Natco Pharma has launched Bosentan tablets, a generic version of Tracleer, in the US for treating pulmonary arterial hypertension in young patients. This launch comes with 180-day exclusivity. Lupin Ltd. is Natco's marketing partner for this product. The d
Announcement as on 20 August 2025

Natco Pharma to buy over 35% in South Africa's Adcock Ingram
Natco Pharma, based in Hyderabad, is set to acquire a 35.75% stake in Adcock Ingram, South Africa's second-largest drugmaker, for ₹2,000 crore. This all-cash deal provides Natco Pharma with a strong entry into high-growth African markets and expands its
Announcement as on 24 July 2025

Natco Pharma offers to acquire nearly 36% stake in Adcock Ingram in Rs 2,100-cr deal
Natco Pharma has made a firm offer to acquire nearly 36% stake in South African drug firm Adcock Ingram Holdings for up to Rs 2,100 crore. This acquisition will provide Natco Pharma with a strong entry into the Southern African market and expand its footpr
Announcement as on 23 July 2025

Announcements by Natco Pharm first page | Next page | Prev page |

524816 Natco Pharm current price & indicator signals

Moving Averages for Natco Pharm

  • 5Day Average: 914.21
  • 12Day Average: 914.88
  • 20Day Average: 914.56
  • 50Day Average: 865.49
  • 100Day Average: 863.8
  • 150Day Average: 886
  • 200Day Average: 870

524816 Indicators & signals

Indicator MACD (12,26,9)

910.62, 898.48, 16.24
Indicator MACD is in positive zone

Indicator ADX (14)

14.38, 26.73, 20.01
Indicator ADX is indicating that momentum is weak.
Indicator ADX is showing that momentum is towards buying

Indicator RSI (14)

Current RSI is: 55
Indicator RSI is indicating buying momentum and stock might rise.

Recent prices of 524816 Natco Pharm are as follows: Daily volume is divided by 10 day averaged volume

Date Close Range Change % Volume
29 Mon Dec 2025 895.90 894.20 to 911.30 -1.34% 0.44 times
26 Fri Dec 2025 908.10 905.70 to 920.00 -0.89% 0.72 times
24 Wed Dec 2025 916.25 911.50 to 926.70 -1.18% 0.91 times
23 Tue Dec 2025 927.15 922.50 to 950.40 0.38% 0.55 times
22 Mon Dec 2025 923.65 910.90 to 927.00 0.63% 0.95 times
19 Fri Dec 2025 917.90 913.10 to 943.00 0.33% 1.14 times
18 Thu Dec 2025 914.85 910.95 to 924.35 -0.83% 0.87 times
17 Wed Dec 2025 922.50 913.05 to 929.40 0.05% 1 times
16 Tue Dec 2025 922.05 904.45 to 928.00 1.87% 1.1 times
15 Mon Dec 2025 905.10 895.55 to 918.00 -0.11% 1.03 times
12 Fri Dec 2025 906.10 900.95 to 923.85 -1.4% 1.73 times
11 Thu Dec 2025 918.95 866.70 to 933.25 5.93% 5.61 times

Videos related to: 524816 announcements Natco Pharm announcements and dividends declared BSE

Hindi Video Correct Way Of Fundamental Analysis Using EPS And PE - MunafaSutra

Hindi Video What Is Needed To Succeed In Stock Markets

524816 announcements Natco Pharm announcements and dividends declared BSE

 

Back to top